[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBwA7Ab4G5OKE909XNmcKO9YgSL3Jj1zb7IbfwNmr-EU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",[4],207,false,53,9,146690,19,170,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Endometriosis",12,{"name":18,"count":19},"Celiac Disease",8,{"name":21,"count":22},"COVID-19",7,{"name":24,"count":25},"Acute Respiratory Failure",5,{"name":27,"count":25},"Parkinson Disease",{"name":29,"count":30},"Septic Shock",4,{"name":32,"count":30},"Hepatitis D",{"name":34,"count":30},"Endometriosis-related Pain",[36,41,46,51,55,60,65,69,74,79],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06122285","Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)","2023-11-01","Bulevirtide",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06661382","Use of Platelet Rich Plasma from Cord Blood Vs Placebo in the Treatment of Vulvar Lichen Sclerosus","2024-11-24","Infiltrative treatment with CB-PRP",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT05813184","Prenatal Antibiotics and Breast Milk \u002F Neonatal IgA","2025-04-30","Antibiotics",{"nctId":52,"briefTitle":53,"date":54,"intervention":40},"NCT06504485","Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment","2025-11-30",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06346418","Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks","2025-12","WES analysis",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07204093","Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis","2026-02","Drospirenone 4 mg orally",{"nctId":66,"briefTitle":67,"date":68,"intervention":40},"NCT06397859","Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis","2026-06-30",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06635525","Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination","2026-07","Influenza vaccination",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT06566105","The Liver BIoBank Lombardia of Fatty Liver","2030-06-30","precision medicine approach",{"nctId":80,"briefTitle":81,"date":82,"intervention":83},"NCT06856252","Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)","2030-07-31","Liver resection to isolate cells",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,117,163,185,203,227,250,268,291,309,335,356,381,418,436,454,472,490,508,526,551,579,605,631,658,683,709,733,763,781,799,817,849,867,885,903,921,939,964,989,1015,1041,1069,1096,1114,1139,1164,1190,1215,1233,1258,1289,1313],{"intervention":45,"totalTrials":93,"cells":94},1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":111,"PHASE4":113,"NA":115},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":93,"soonestReadout":44},[102],{"nctId":42,"briefTitle":43,"status":103,"phases":104,"primaryCompletion":44,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"RECRUITING",[86,87],"2024-12-24","2023-01-24",100,[109],"Vulvar Lichen Sclerosus",[45],{"trials":112,"activeCount":97},[],{"trials":114,"activeCount":97},[],{"trials":116,"activeCount":97},[],{"intervention":40,"totalTrials":30,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":129},{"trials":120,"activeCount":97},[],{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":97},[],{"trials":130,"activeCount":162,"soonestReadout":39},[131,142,149,155],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":141},"NCT05962307","Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy","COMPLETED",[],"2023-04-30","2023-05-31","2023-04-01",50,[32],[40],{"nctId":52,"briefTitle":53,"status":103,"phases":143,"primaryCompletion":54,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":148},[],"2026-02-28","2024-09-01",192,[32],[40],{"nctId":37,"briefTitle":38,"status":103,"phases":150,"primaryCompletion":39,"completion":151,"start":152,"enrollment":107,"conditions":153,"interventions":154},[],"2025-12-31","2023-05-01",[32],[40],{"nctId":66,"briefTitle":67,"status":103,"phases":156,"primaryCompletion":68,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},[],"2026-08-31","2024-05-06",266,[32],[40],3,{"intervention":64,"totalTrials":93,"cells":164},{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":166,"activeCount":97},[],{"trials":168,"activeCount":97},[],{"trials":170,"activeCount":97},[],{"trials":172,"activeCount":97},[],{"trials":174,"activeCount":97},[],{"trials":176,"activeCount":93,"soonestReadout":63},[177],{"nctId":61,"briefTitle":62,"status":178,"phases":179,"primaryCompletion":63,"completion":63,"start":180,"enrollment":181,"conditions":182,"interventions":183},"ACTIVE_NOT_RECRUITING",[],"2025-08-11",138,[15],[64,184],"Dienogest 2 mg orally",{"intervention":184,"totalTrials":93,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":188,"activeCount":97},[],{"trials":190,"activeCount":97},[],{"trials":192,"activeCount":97},[],{"trials":194,"activeCount":97},[],{"trials":196,"activeCount":97},[],{"trials":198,"activeCount":93,"soonestReadout":63},[199],{"nctId":61,"briefTitle":62,"status":178,"phases":200,"primaryCompletion":63,"completion":63,"start":180,"enrollment":181,"conditions":201,"interventions":202},[],[15],[64,184],{"intervention":78,"totalTrials":93,"cells":204},{"EARLY_PHASE1":205,"PHASE1":207,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":206,"activeCount":97},[],{"trials":208,"activeCount":97},[],{"trials":210,"activeCount":97},[],{"trials":212,"activeCount":97},[],{"trials":214,"activeCount":97},[],{"trials":216,"activeCount":93,"soonestReadout":77},[217],{"nctId":75,"briefTitle":76,"status":103,"phases":218,"primaryCompletion":77,"completion":219,"start":220,"enrollment":221,"conditions":222,"interventions":226},[90],"2037-12-31","2020-06-01",2500,[223,224,225],"NAFLD","Precision Medicine","Cardiovascular Diseases",[78],{"intervention":73,"totalTrials":93,"cells":228},{"EARLY_PHASE1":229,"PHASE1":231,"PHASE2":233,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":230,"activeCount":97},[],{"trials":232,"activeCount":97},[],{"trials":234,"activeCount":97},[],{"trials":236,"activeCount":97},[],{"trials":238,"activeCount":97},[],{"trials":240,"activeCount":93,"soonestReadout":72},[241],{"nctId":70,"briefTitle":71,"status":103,"phases":242,"primaryCompletion":72,"completion":72,"start":243,"enrollment":244,"conditions":245,"interventions":248},[],"2024-10-16",146,[246,247],"Chronic Kidney Disease Requiring Chronic Dialysis","Vaccine Response",[73,249],"SARS-CoV-2 vaccine",{"intervention":249,"totalTrials":93,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":258,"PHASE4":260,"NA":262},{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":97},[],{"trials":257,"activeCount":97},[],{"trials":259,"activeCount":97},[],{"trials":261,"activeCount":97},[],{"trials":263,"activeCount":93,"soonestReadout":72},[264],{"nctId":70,"briefTitle":71,"status":103,"phases":265,"primaryCompletion":72,"completion":72,"start":243,"enrollment":244,"conditions":266,"interventions":267},[],[246,247],[73,249],{"intervention":59,"totalTrials":93,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":278,"NA":280},{"trials":271,"activeCount":97},[],{"trials":273,"activeCount":97},[],{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":97},[],{"trials":279,"activeCount":97},[],{"trials":281,"activeCount":93,"soonestReadout":58},[282],{"nctId":56,"briefTitle":57,"status":103,"phases":283,"primaryCompletion":58,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":289},[90],"2026-01","2023-05-19",208,[288],"Beckwith-Wiedemann Syndrome",[59,290],"whole-genome methylation analysis",{"intervention":290,"totalTrials":93,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":297,"PHASE3":299,"PHASE4":301,"NA":303},{"trials":294,"activeCount":97},[],{"trials":296,"activeCount":97},[],{"trials":298,"activeCount":97},[],{"trials":300,"activeCount":97},[],{"trials":302,"activeCount":97},[],{"trials":304,"activeCount":93,"soonestReadout":58},[305],{"nctId":56,"briefTitle":57,"status":103,"phases":306,"primaryCompletion":58,"completion":284,"start":285,"enrollment":286,"conditions":307,"interventions":308},[90],[288],[59,290],{"intervention":50,"totalTrials":93,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":312,"activeCount":97},[],{"trials":314,"activeCount":97},[],{"trials":316,"activeCount":97},[],{"trials":318,"activeCount":97},[],{"trials":320,"activeCount":97},[],{"trials":322,"activeCount":93,"soonestReadout":49},[323],{"nctId":47,"briefTitle":48,"status":103,"phases":324,"primaryCompletion":49,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":334},[],"2025-10-30","2023-10-08",82,[329,330,331,332,333],"Prenatal Exposure Delayed Effects","Antibiotic Prophylaxis","Dysbiosis","Neonatal Infection","Breast Milk; Noxious Influence, Affecting Fetus",[50],{"intervention":83,"totalTrials":93,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":347},{"trials":338,"activeCount":97},[],{"trials":340,"activeCount":97},[],{"trials":342,"activeCount":97},[],{"trials":344,"activeCount":97},[],{"trials":346,"activeCount":97},[],{"trials":348,"activeCount":93,"soonestReadout":82},[349],{"nctId":80,"briefTitle":81,"status":103,"phases":350,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":355},[90],"2032-07-31","2021-07-01",60,[223],[83],{"intervention":357,"totalTrials":93,"cells":358},"Whole exome sequencing - WES",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":360,"activeCount":97},[],{"trials":362,"activeCount":97},[],{"trials":364,"activeCount":97},[],{"trials":366,"activeCount":97},[],{"trials":368,"activeCount":97},[],{"trials":370,"activeCount":93,"soonestReadout":375},[371],{"nctId":372,"briefTitle":373,"status":178,"phases":374,"primaryCompletion":375,"completion":376,"start":144,"enrollment":377,"conditions":378,"interventions":380},"NCT07615244","STUDY OF MICROVASCULAR DAMAGE IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA",[90],"2031-01-31","2032-01-31",79,[379],"TTP - Thrombotic Thrombocytopenic Purpura",[357],{"intervention":382,"totalTrials":93,"cells":383},"cytokine essays",{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":385,"activeCount":97},[],{"trials":387,"activeCount":97},[],{"trials":389,"activeCount":97},[],{"trials":391,"activeCount":97},[],{"trials":393,"activeCount":97},[],{"trials":395,"activeCount":93,"soonestReadout":400},[396],{"nctId":397,"briefTitle":398,"status":103,"phases":399,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":411},"NCT05931718","Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic\u002FAutoimmune Neutropenia",[],"2030-09","2035-06","2019-06-01",200,[405,406,407,408,409,410],"Autoimmune Hemolytic Anemia","Immune Thrombocytopenia","Chronic Idiopathic Neutropenia","Autoimmune Neutropenia","Myelodysplastic Syndromes","Cold Agglutinin Disease",[382,412,413,414,415,416,417],"NGS","Fecal microbiome","Erythropoietin","Luspatercept","Thrombopoietin Receptor Agonist","G-CSF",{"intervention":412,"totalTrials":93,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":421,"activeCount":97},[],{"trials":423,"activeCount":97},[],{"trials":425,"activeCount":97},[],{"trials":427,"activeCount":97},[],{"trials":429,"activeCount":97},[],{"trials":431,"activeCount":93,"soonestReadout":400},[432],{"nctId":397,"briefTitle":398,"status":103,"phases":433,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":434,"interventions":435},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":413,"totalTrials":93,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":446,"NA":448},{"trials":439,"activeCount":97},[],{"trials":441,"activeCount":97},[],{"trials":443,"activeCount":97},[],{"trials":445,"activeCount":97},[],{"trials":447,"activeCount":97},[],{"trials":449,"activeCount":93,"soonestReadout":400},[450],{"nctId":397,"briefTitle":398,"status":103,"phases":451,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":452,"interventions":453},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":414,"totalTrials":93,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":457,"activeCount":97},[],{"trials":459,"activeCount":97},[],{"trials":461,"activeCount":97},[],{"trials":463,"activeCount":97},[],{"trials":465,"activeCount":97},[],{"trials":467,"activeCount":93,"soonestReadout":400},[468],{"nctId":397,"briefTitle":398,"status":103,"phases":469,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":470,"interventions":471},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":415,"totalTrials":93,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":475,"activeCount":97},[],{"trials":477,"activeCount":97},[],{"trials":479,"activeCount":97},[],{"trials":481,"activeCount":97},[],{"trials":483,"activeCount":97},[],{"trials":485,"activeCount":93,"soonestReadout":400},[486],{"nctId":397,"briefTitle":398,"status":103,"phases":487,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":488,"interventions":489},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":416,"totalTrials":93,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":493,"activeCount":97},[],{"trials":495,"activeCount":97},[],{"trials":497,"activeCount":97},[],{"trials":499,"activeCount":97},[],{"trials":501,"activeCount":97},[],{"trials":503,"activeCount":93,"soonestReadout":400},[504],{"nctId":397,"briefTitle":398,"status":103,"phases":505,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":506,"interventions":507},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":417,"totalTrials":93,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":511,"activeCount":97},[],{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":97},[],{"trials":519,"activeCount":97},[],{"trials":521,"activeCount":93,"soonestReadout":400},[522],{"nctId":397,"briefTitle":398,"status":103,"phases":523,"primaryCompletion":400,"completion":401,"start":402,"enrollment":403,"conditions":524,"interventions":525},[],[405,406,407,408,409,410],[382,412,413,414,415,416,417],{"intervention":527,"totalTrials":93,"cells":528},"ultra-micronized palmitoylethanolamide",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":549},{"trials":530,"activeCount":97},[],{"trials":532,"activeCount":97},[],{"trials":534,"activeCount":97},[],{"trials":536,"activeCount":97},[],{"trials":538,"activeCount":97},[539],{"nctId":540,"briefTitle":541,"status":134,"phases":542,"primaryCompletion":543,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT02699281","Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain",[89],"2016-07","2015-10",11,[547],"Chronic Pain",[527],{"trials":550,"activeCount":97},[],{"intervention":552,"totalTrials":93,"cells":553},"Aripiprazole",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":577},{"trials":555,"activeCount":97},[],{"trials":557,"activeCount":97},[],{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[564],{"nctId":565,"briefTitle":566,"status":134,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":571,"conditions":572,"interventions":576},"NCT05322031","The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia",[89],"2024-08-31","2024-11-30","2022-08-01",15,[573,574,575],"Schizophrenia","Myelin Degeneration","Cognition Disorder",[552],{"trials":578,"activeCount":97},[],{"intervention":580,"totalTrials":93,"cells":581},"Diclofenac",{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":590,"NA":603},{"trials":583,"activeCount":97},[],{"trials":585,"activeCount":97},[],{"trials":587,"activeCount":97},[],{"trials":589,"activeCount":97},[],{"trials":591,"activeCount":97},[592],{"nctId":593,"briefTitle":594,"status":595,"phases":596,"completion":597,"start":598,"conditions":599,"interventions":602},"NCT00491192","Normothermia in Patients With Acute Cerebral Damage","UNKNOWN",[89],"2009-06","2007-06",[600,601],"Traumatic Brain Injury","Subarachnoid Hemorrhage",[580],{"trials":604,"activeCount":97},[],{"intervention":606,"totalTrials":93,"cells":607},"Plasma-derived FVIII\u002FVWF concentrate",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":629},{"trials":609,"activeCount":97},[],{"trials":611,"activeCount":97},[],{"trials":613,"activeCount":97},[],{"trials":615,"activeCount":97},[],{"trials":617,"activeCount":97},[618],{"nctId":619,"briefTitle":620,"status":595,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":625,"conditions":626,"interventions":628},"NCT02479087","Safety\u002FEfficacy Study to Assess Whether FVIII\u002FVWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients",[89],"2019-01","2020-01","2015-01",20,[627],"Hemophilia A",[606],{"trials":630,"activeCount":97},[],{"intervention":632,"totalTrials":93,"cells":633},"Venlafaxine",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":640,"PHASE4":642,"NA":656},{"trials":635,"activeCount":97},[],{"trials":637,"activeCount":97},[],{"trials":639,"activeCount":97},[],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":97},[644],{"nctId":645,"briefTitle":646,"status":595,"phases":647,"primaryCompletion":648,"completion":649,"start":650,"enrollment":651,"conditions":652,"interventions":655},"NCT06131268","The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN)",[89],"2024-03-01","2024-04-01","2022-03-01",30,[653,654],"Major Depressive Disorder","Bipolar Affective Disorder, Currently Depressed, Moderate",[632],{"trials":657,"activeCount":97},[],{"intervention":659,"totalTrials":93,"cells":660},"Lurasidone",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":681},{"trials":662,"activeCount":97},[],{"trials":664,"activeCount":97},[],{"trials":666,"activeCount":97},[],{"trials":668,"activeCount":97},[],{"trials":670,"activeCount":97},[671],{"nctId":672,"briefTitle":673,"status":595,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":680},"NCT05351736","Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)",[89],"2024-01-28","2024-04-28","2022-01-26",10,[573],[659],{"trials":682,"activeCount":97},[],{"intervention":684,"totalTrials":93,"cells":685},"L-arginine and liposomal vitamin C",{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":692,"PHASE4":705,"NA":707},{"trials":687,"activeCount":97},[],{"trials":689,"activeCount":97},[],{"trials":691,"activeCount":97},[],{"trials":693,"activeCount":97},[694],{"nctId":695,"briefTitle":696,"status":595,"phases":697,"primaryCompletion":698,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT06044194","Evaluation of the Effect of Liposomal L-Arg and Vit C Integration on Mitochondrial Function in Patients With Heart Failure",[88],"2024-09-30","2024-10-31","2023-03-21",56,[703],"Heart Failure",[684],{"trials":706,"activeCount":97},[],{"trials":708,"activeCount":97},[],{"intervention":710,"totalTrials":93,"cells":711},"Albumin",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":718,"PHASE4":729,"NA":731},{"trials":713,"activeCount":97},[],{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":97},[720],{"nctId":721,"briefTitle":722,"status":134,"phases":723,"primaryCompletion":699,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT03654001","ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)",[88],"2025-01-31","2019-05-07",1319,[29],[710],{"trials":730,"activeCount":97},[],{"trials":732,"activeCount":97},[],{"intervention":734,"totalTrials":93,"cells":735},"nitrofurantoin",{"EARLY_PHASE1":736,"PHASE1":738,"PHASE2":740,"PHASE3":742,"PHASE4":759,"NA":761},{"trials":737,"activeCount":97},[],{"trials":739,"activeCount":97},[],{"trials":741,"activeCount":97},[],{"trials":743,"activeCount":97},[744],{"nctId":745,"briefTitle":746,"status":595,"phases":747,"primaryCompletion":623,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":755},"NCT02021006","Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract",[88],"2025-01","2013-12",292,[752,753,754],"Vesicoureteral Reflux","Renal Hypodysplasia, Nonsyndromic, 1","Chronic Kidney Disease",[734,756,757,758],"Amoxicillin-Potassium Clavulanate Combination","Trimethoprim\u002Fsulfamethoxazole","Cefixime",{"trials":760,"activeCount":97},[],{"trials":762,"activeCount":97},[],{"intervention":756,"totalTrials":93,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":769,"PHASE3":771,"PHASE4":777,"NA":779},{"trials":766,"activeCount":97},[],{"trials":768,"activeCount":97},[],{"trials":770,"activeCount":97},[],{"trials":772,"activeCount":97},[773],{"nctId":745,"briefTitle":746,"status":595,"phases":774,"primaryCompletion":623,"completion":748,"start":749,"enrollment":750,"conditions":775,"interventions":776},[88],[752,753,754],[734,756,757,758],{"trials":778,"activeCount":97},[],{"trials":780,"activeCount":97},[],{"intervention":757,"totalTrials":93,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":795,"NA":797},{"trials":784,"activeCount":97},[],{"trials":786,"activeCount":97},[],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[791],{"nctId":745,"briefTitle":746,"status":595,"phases":792,"primaryCompletion":623,"completion":748,"start":749,"enrollment":750,"conditions":793,"interventions":794},[88],[752,753,754],[734,756,757,758],{"trials":796,"activeCount":97},[],{"trials":798,"activeCount":97},[],{"intervention":758,"totalTrials":93,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":813,"NA":815},{"trials":802,"activeCount":97},[],{"trials":804,"activeCount":97},[],{"trials":806,"activeCount":97},[],{"trials":808,"activeCount":97},[809],{"nctId":745,"briefTitle":746,"status":595,"phases":810,"primaryCompletion":623,"completion":748,"start":749,"enrollment":750,"conditions":811,"interventions":812},[88],[752,753,754],[734,756,757,758],{"trials":814,"activeCount":97},[],{"trials":816,"activeCount":97},[],{"intervention":818,"totalTrials":93,"cells":819},"Phenylephrine",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":845,"NA":847},{"trials":821,"activeCount":97},[],{"trials":823,"activeCount":97},[],{"trials":825,"activeCount":97},[],{"trials":827,"activeCount":97},[828],{"nctId":829,"briefTitle":830,"status":831,"phases":832,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":837,"interventions":839},"NCT02428062","Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly","SUSPENDED",[87,88],"2018-12","2019-12","2014-10",1812,[838],"Post-operative Cognitive Dysfunction",[818,840,841,842,843,844],"Intravenous fluids","Ephedrine","Epinephrine","Norepinephrine","Dopamine",{"trials":846,"activeCount":97},[],{"trials":848,"activeCount":97},[],{"intervention":840,"totalTrials":93,"cells":850},{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":863,"NA":865},{"trials":852,"activeCount":97},[],{"trials":854,"activeCount":97},[],{"trials":856,"activeCount":97},[],{"trials":858,"activeCount":97},[859],{"nctId":829,"briefTitle":830,"status":831,"phases":860,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":861,"interventions":862},[87,88],[838],[818,840,841,842,843,844],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"intervention":841,"totalTrials":93,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":881,"NA":883},{"trials":870,"activeCount":97},[],{"trials":872,"activeCount":97},[],{"trials":874,"activeCount":97},[],{"trials":876,"activeCount":97},[877],{"nctId":829,"briefTitle":830,"status":831,"phases":878,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":879,"interventions":880},[87,88],[838],[818,840,841,842,843,844],{"trials":882,"activeCount":97},[],{"trials":884,"activeCount":97},[],{"intervention":842,"totalTrials":93,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":899,"NA":901},{"trials":888,"activeCount":97},[],{"trials":890,"activeCount":97},[],{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":97},[895],{"nctId":829,"briefTitle":830,"status":831,"phases":896,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":897,"interventions":898},[87,88],[838],[818,840,841,842,843,844],{"trials":900,"activeCount":97},[],{"trials":902,"activeCount":97},[],{"intervention":843,"totalTrials":93,"cells":904},{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":917,"NA":919},{"trials":906,"activeCount":97},[],{"trials":908,"activeCount":97},[],{"trials":910,"activeCount":97},[],{"trials":912,"activeCount":97},[913],{"nctId":829,"briefTitle":830,"status":831,"phases":914,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":915,"interventions":916},[87,88],[838],[818,840,841,842,843,844],{"trials":918,"activeCount":97},[],{"trials":920,"activeCount":97},[],{"intervention":844,"totalTrials":93,"cells":922},{"EARLY_PHASE1":923,"PHASE1":925,"PHASE2":927,"PHASE3":929,"PHASE4":935,"NA":937},{"trials":924,"activeCount":97},[],{"trials":926,"activeCount":97},[],{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":97},[931],{"nctId":829,"briefTitle":830,"status":831,"phases":932,"primaryCompletion":833,"completion":834,"start":835,"enrollment":836,"conditions":933,"interventions":934},[87,88],[838],[818,840,841,842,843,844],{"trials":936,"activeCount":97},[],{"trials":938,"activeCount":97},[],{"intervention":940,"totalTrials":93,"cells":941},"LAB4",{"EARLY_PHASE1":942,"PHASE1":944,"PHASE2":946,"PHASE3":958,"PHASE4":960,"NA":962},{"trials":943,"activeCount":97},[],{"trials":945,"activeCount":97},[],{"trials":947,"activeCount":97},[948],{"nctId":949,"briefTitle":950,"status":595,"phases":951,"primaryCompletion":952,"completion":953,"start":954,"enrollment":353,"conditions":955,"interventions":957},"NCT02373995","Role of the Microbiome in Graves' Orbitopathy",[86,87],"2015-07","2016-12","2015-02",[956],"Graves' Disease",[940],{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":97},[],{"trials":963,"activeCount":97},[],{"intervention":965,"totalTrials":93,"cells":966},"recombinant activated factor VII",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":983,"PHASE4":985,"NA":987},{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[973],{"nctId":974,"briefTitle":975,"status":595,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":139,"conditions":980,"interventions":982},"NCT01105546","rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors",[87],"2014-02","2014-04","2010-12",[981],"Hemophilia A With Inhibitors",[965,965],{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[],{"trials":988,"activeCount":97},[],{"intervention":990,"totalTrials":93,"cells":991},"Potassium Canrenoate",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":1009,"PHASE4":1011,"NA":1013},{"trials":993,"activeCount":97},[],{"trials":995,"activeCount":97},[],{"trials":997,"activeCount":97},[998],{"nctId":999,"briefTitle":1000,"status":595,"phases":1001,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":1005,"conditions":1006,"interventions":1008},"NCT04977960","Efficacy of Canrenone as add-on Treatment in Moderate to Severe ARDS in COVID-19",[87],"2023-05","2023-12","2022-09",180,[1007],"COVID-19 Acute Respiratory Distress Syndrome",[990],{"trials":1010,"activeCount":97},[],{"trials":1012,"activeCount":97},[],{"trials":1014,"activeCount":97},[],{"intervention":1016,"totalTrials":93,"cells":1017},"prednisone, low dose rituximab",{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":97},[],{"trials":1023,"activeCount":97},[1024],{"nctId":1025,"briefTitle":1026,"status":134,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":1031,"conditions":1032,"interventions":1034},"NCT01345708","A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia",[87],"2010-01","2011-01","2009-01",23,[1033],"Autoimmune Hemolytic Disease (Cold Type) (Warm Type)",[1016],{"trials":1036,"activeCount":97},[],{"trials":1038,"activeCount":97},[],{"trials":1040,"activeCount":97},[],{"intervention":1042,"totalTrials":93,"cells":1043},"Pembrolizumab + Lenvatinib",{"EARLY_PHASE1":1044,"PHASE1":1046,"PHASE2":1048,"PHASE3":1063,"PHASE4":1065,"NA":1067},{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[1050],{"nctId":1051,"briefTitle":1052,"status":1053,"phases":1054,"primaryCompletion":1055,"completion":1056,"start":1057,"enrollment":97,"conditions":1058,"interventions":1062},"NCT05846724","Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma","WITHDRAWN",[87],"2029-02-01","2030-02-01","2024-02-01",[1059,1060,1061],"Kaposi Sarcoma","Classic Kaposi Sarcoma","Refractory Kaposi Sarcoma",[1042],{"trials":1064,"activeCount":97},[],{"trials":1066,"activeCount":97},[],{"trials":1068,"activeCount":97},[],{"intervention":1070,"totalTrials":93,"cells":1071},"Tocilizumab 20 Mg\u002FmL Intravenous Solution",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1090,"PHASE4":1092,"NA":1094},{"trials":1073,"activeCount":97},[],{"trials":1075,"activeCount":97},[],{"trials":1077,"activeCount":97},[1078],{"nctId":1079,"briefTitle":1080,"status":595,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1088},"NCT04876534","Tocilizumab in Active Moderate-severe Graves' Orbitopathy",[87],"2022-12-18","2023-12-18","2019-12-18",64,[1087],"Graves Ophthalmopathy",[1070,1089],"MethylPREDNISolone Injectable Solution",{"trials":1091,"activeCount":97},[],{"trials":1093,"activeCount":97},[],{"trials":1095,"activeCount":97},[],{"intervention":1089,"totalTrials":93,"cells":1097},{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1099,"activeCount":97},[],{"trials":1101,"activeCount":97},[],{"trials":1103,"activeCount":97},[1104],{"nctId":1079,"briefTitle":1080,"status":595,"phases":1105,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1106,"interventions":1107},[87],[1087],[1070,1089],{"trials":1109,"activeCount":97},[],{"trials":1111,"activeCount":97},[],{"trials":1113,"activeCount":97},[],{"intervention":1115,"totalTrials":93,"cells":1116},"stem cell therapy",{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1118,"activeCount":97},[],{"trials":1120,"activeCount":97},[],{"trials":1122,"activeCount":97},[1123],{"nctId":1124,"briefTitle":1125,"status":595,"phases":1126,"primaryCompletion":1127,"completion":1127,"start":1128,"enrollment":1129,"conditions":1130,"interventions":1132},"NCT01824121","Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism",[86,87],"2014-12","2012-12",25,[1131],"Progressive Supranuclear Palsy",[1115],{"trials":1134,"activeCount":97},[],{"trials":1136,"activeCount":97},[],{"trials":1138,"activeCount":97},[],{"intervention":1140,"totalTrials":93,"cells":1141},"genetic determinants to develop respiratory failure",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1148,"PHASE4":1150,"NA":1152},{"trials":1143,"activeCount":97},[],{"trials":1145,"activeCount":97},[],{"trials":1147,"activeCount":97},[],{"trials":1149,"activeCount":97},[],{"trials":1151,"activeCount":97},[],{"trials":1153,"activeCount":97},[1154],{"nctId":1155,"briefTitle":1156,"status":134,"phases":1157,"primaryCompletion":1158,"completion":137,"start":1159,"enrollment":1160,"conditions":1161,"interventions":1163},"NCT06549712","The Fondazione Genomic SARS-CoV-2 Study COVID-19",[90],"2021-01-31","2020-03-23",4000,[21,1162],"Genetic Predisposition",[1140,1140,1140],{"intervention":1165,"totalTrials":93,"cells":1166},"Iron sulfate 105 mg",{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1168,"activeCount":97},[],{"trials":1170,"activeCount":97},[],{"trials":1172,"activeCount":97},[],{"trials":1174,"activeCount":97},[],{"trials":1176,"activeCount":97},[],{"trials":1178,"activeCount":97},[1179],{"nctId":1180,"briefTitle":1181,"status":595,"phases":1182,"primaryCompletion":1183,"completion":1184,"start":1185,"enrollment":1186,"conditions":1187,"interventions":1189},"NCT02949765","Effects of a Dietary Approach to Iron Deficiency in Premenopausal Women Affected by Celiac Disease",[90],"2017-06","2017-09","2015-12",35,[18,1188],"Iron Deficiency (Without Anemia)",[1165],{"intervention":1191,"totalTrials":93,"cells":1192},"Clomifene Citrate",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1201,"NA":1203},{"trials":1194,"activeCount":97},[],{"trials":1196,"activeCount":97},[],{"trials":1198,"activeCount":97},[],{"trials":1200,"activeCount":97},[],{"trials":1202,"activeCount":97},[],{"trials":1204,"activeCount":97},[1205],{"nctId":1206,"briefTitle":1207,"status":134,"phases":1208,"primaryCompletion":979,"completion":979,"start":1209,"enrollment":1210,"conditions":1211,"interventions":1213},"NCT01389713","Clomifene Citrate as First Line Treatment in in Vitro Fertilization Cycles for Patients With Lower Ovarian Reserve",[90],"2008-09",289,[1212],"Infertility",[1191,1214],"GnRH analog and recombinant human FSH",{"intervention":1214,"totalTrials":93,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1225,"NA":1227},{"trials":1218,"activeCount":97},[],{"trials":1220,"activeCount":97},[],{"trials":1222,"activeCount":97},[],{"trials":1224,"activeCount":97},[],{"trials":1226,"activeCount":97},[],{"trials":1228,"activeCount":97},[1229],{"nctId":1206,"briefTitle":1207,"status":134,"phases":1230,"primaryCompletion":979,"completion":979,"start":1209,"enrollment":1210,"conditions":1231,"interventions":1232},[90],[1212],[1191,1214],{"intervention":1234,"totalTrials":93,"cells":1235},"genetic model",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1244,"NA":1246},{"trials":1237,"activeCount":97},[],{"trials":1239,"activeCount":97},[],{"trials":1241,"activeCount":97},[],{"trials":1243,"activeCount":97},[],{"trials":1245,"activeCount":97},[],{"trials":1247,"activeCount":97},[1248],{"nctId":1249,"briefTitle":1250,"status":134,"phases":1251,"primaryCompletion":1252,"completion":1253,"start":1254,"enrollment":651,"conditions":1255,"interventions":1257},"NCT06311396","Development of a Neuronal Microscope",[90],"2024-01-01","2025-01-01","2021-01-01",[1256],"Hepatic Carcinoma",[1234],{"intervention":1259,"totalTrials":93,"cells":1260},"COVID19 mRNA vaccine",{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1269,"NA":1271},{"trials":1262,"activeCount":97},[],{"trials":1264,"activeCount":97},[],{"trials":1266,"activeCount":97},[],{"trials":1268,"activeCount":97},[],{"trials":1270,"activeCount":97},[],{"trials":1272,"activeCount":97},[1273],{"nctId":1274,"briefTitle":1275,"status":134,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1288},"NCT05116748","COVID19 Vaccine in SOT Adult Recipients",[],"2022-12-30","2023-12-31","2021-10-01",364,[21,1282,1283,1284,1285,1286,1287],"Vaccine Adverse Reaction","Vaccine Response Impaired","Vaccine Reaction","Lung Transplant; Complications","Liver Transplant; Complications","Vaccination",[1259],{"intervention":1290,"totalTrials":93,"cells":1291},"Citalopram",{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1293,"activeCount":97},[],{"trials":1295,"activeCount":97},[],{"trials":1297,"activeCount":97},[],{"trials":1299,"activeCount":97},[],{"trials":1301,"activeCount":97},[],{"trials":1303,"activeCount":97},[1304],{"nctId":1305,"briefTitle":1306,"status":595,"phases":1307,"primaryCompletion":1308,"completion":1309,"start":1252,"enrollment":571,"conditions":1310,"interventions":1312},"NCT06131255","DRACULA1 Partum Depression: an Integrated Molecular-pharmaco-imaging Study\")",[],"2025-12-01","2026-04-30",[1311],"Post-partum Depression",[1290],{"intervention":1314,"totalTrials":93,"cells":1315},"Sulphate iron",{"EARLY_PHASE1":1316,"PHASE1":1318,"PHASE2":1320,"PHASE3":1322,"PHASE4":1324,"NA":1326},{"trials":1317,"activeCount":97},[],{"trials":1319,"activeCount":97},[],{"trials":1321,"activeCount":97},[],{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[1328],{"nctId":1329,"briefTitle":1330,"status":595,"phases":1331,"primaryCompletion":1332,"completion":1333,"start":1334,"enrollment":625,"conditions":1335,"interventions":1337},"NCT02916654","Sucrosomial Iron in Patients With Celiac Disease and IDA",[90],"2016-08","2017-12","2015-04",[18,1336],"Iron Deficiency Anemia",[1314]]